Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
-
New antibody drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called TQB2210 in 16 people with advanced cancers that had not responded to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block their growth. The main goals were to find a saf…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New injection shows promise for sinus sufferers
Disease control CompletedThis study tested a new medicine called TQC2731, given as an injection, to see if it is safe and works well for people with long-term sinus inflammation and nasal polyps (growths in the nose). The trial involved 59 adults who had already completed a previous study of the same dru…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New allergy shot shows promise in phase 2 trial
Symptom relief CompletedThis study tested an injection called TQC2938 in 136 adults with seasonal allergic rhinitis (hay fever). All participants also used a standard nasal spray. The goal was to see if the injection reduces nasal symptoms like sneezing and congestion better than a placebo. The trial is…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 16, 2026 12:52 UTC
-
New psoriasis pill shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The goal was to see if the drug could safely clear skin symptoms like red, scaly patches. Researchers measured how many people achieved at least a 75% improvement in thei…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 15, 2026 19:06 UTC